Share Email Print
cover

Proceedings Paper

Assessment of surface concentrations in resorbable ocular implants: controlled drug delivery devices for 5-fluorouracil (5-FU)
Author(s): Peter J. Milne; Sandrine Gautier; Jean-Marie A. Parel; Valerie Jallet
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The antineoplastic drug 5-fluorouracil (5-fluoro- 2,4,(1H,3H)-pyrimidinedione; 5-FU) has been used to control proliferation of penetrating fibroblasts and to prevent channel closure following glaucoma filtration surgery (trabeculectomy) or laser sclerectomy. Because of the toxicity of the drug, administration of low dosages slowly over time, at the site of the desired treatment, is indicated for optimum efficacy. Repeated injections of low dosages of the drug represent an undesirable intervention and may also result in unwanted toxicity to the corneal epithelium. A suitable biocompatible and resorbable polymer matrix composed of a poly (D,L-lactic-co-glycolic acid: PLGA) has been admixed with varying amounts of 5-FU and cast as shapes suitable for intracorneal implantation. Slow biodegradation of this polymer over a one to two week period has been shown to result in an acceptably slow drug release mechanism. An issue arising during the clinical evaluation of the efficacy of this drug delivery system was how best to quantify the concentration of 5-FU and its distribution spatially in the solid implant. FT-IR and FT-Raman spectroscopies distinguishes between the drug and the polymer matrix and were used to differentiate and quantitate the 5-FU concentration of the implants.

Paper Details

Date Published: 26 May 1997
PDF: 10 pages
Proc. SPIE 2971, Ophthalmic Technologies VII, (26 May 1997); doi: 10.1117/12.275108
Show Author Affiliations
Peter J. Milne, Univ. of Miami (United States)
Sandrine Gautier, Bascom Palmer Eye Institute/Univ. of Miami School of Medicine (United States)
Jean-Marie A. Parel, Bascom Palmer Eye Institute/Univ. of Miami School of Medicine and College of Engineering (United States)
Valerie Jallet, Corneal Industrie SA (United States)


Published in SPIE Proceedings Vol. 2971:
Ophthalmic Technologies VII
Pascal O. Rol; Karen Margaret Joos; Fabrice Manns, Editor(s)

© SPIE. Terms of Use
Back to Top